Borstkanker: Shenqui Fuzheng injecties verbeteren significant effect van chemo bij borstkanker, vermindert de bijwerkingen, betere kwaliteit van leven en stimuleert de T-lymfocyten waardoor betere immuunstimulatie, aldus 3 gerandomiseerde fase III studies

14 april 2018: Lees ook dit artikel en klik op de volgende link:

https://kanker-actueel.nl/tcm-traditionele-chinese-medicijnen-kruiden-gebruik-naast-chemo-geeft-12-procent-minder-doden-aan-gevorderde-uitgezaaide-borstkanker-over-10-jaar-geregistreerd.html

17 oktober 2008: Bron Pubmed.

Injecties met Shenqui Fuzheng bij borstkankerpatienten verbetert significant de werking van chemo en vermindert de bijwerkingen. Bovendien verbetert Shenqui Fuzheng de T-lymfocyten waardoor het immuunsysteem beter wordt gestimuleert. In 1 studie werd Shenqui Fuzheng gecombineerd met dendritische celtherapie en ook daar verbeterden de resultaten. Hier drie abstracten van gerandomiseerde fase II en III studies bij borstkankerpatienten dit jaar gepubliceerd.

1: J Tradit Chin Med. 2008 Mar;28(1):34-8.

Links

Clinical effects of shenqi fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets.

Dai Z, Wan X, Kang H, Ji Z, Liu L, Liu X, Song L, Min W, Ma X.

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi 'an 710004, China.

OBJECTIVE: To evaluate clinical effects of shenqi fuzheng Injection ([Chinese characters: see text]) in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets.

METHODS: During the period from 2000 to 2005, 126 patients with local advanced breast cancer were treated with the neoadjuvant chemotherapy. They were randomly divided into the following two groups: a control group of 61 cases treated by chemotherapy alone and a study group of 65 cases treated by chemotherapy plus shenqi fuzheng injection. All the cases of both groups were given the CEF (CTX 500 mg/m2, d1,8; EPI 40 mg/m2, d1, 8; and 5-Fu 500 mg/m2 d1,8) regimen. The clinical effects, the effects on T-lymphocyte subgroup and NK cells, and the toxic side effects were observed.

RESULTS: All the patients completed two cycles of the chemotherapy, and the efficacy and the toxic side effects were evaluated. For the primary tumor in the breast, the total effective rate was 69.2% (45/65) in the study group and 49.2% (30/61) in the control group with a statistically significant difference in the intergroup comparison (chi2 = 5.251, P = 0.022, < 0.05). There was no progression of the disease in both the groups, and there were no grade IV toxic side effects in the two groups. The major toxic responses were myelosuppression and gastrointestinal reaction, which were milder in the study group than the control group, and with a shorter recovery course in the former than the latter. Besides, an obvious rise of the T-lymphocyte subgroup and NK cells was found in the study group after the neoadjuvant chemotherapy, with a very significant difference from the controls (P < 0.01).

CONCLUSIONS: Shenqi fuzheng Injection can improve and regulate immune function of the patients with local advanced breast cancer given the neoadjuvant chemotherapy, and therefore it can enhance the curative effect and reduce the side effect as well.

PMID: 18416081 [PubMed - in process]1: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Feb;28(2):152-4. Links

[Effect of shenqi fuzheng injection combined with chemotherapy on thirty patients with advanced breast cancer]

[Article in Chinese]

Huang ZF, Wei JS, Li HZ, et al .

Department of Traditional Chinese Medicine, Affiliated Tumor Hospital of Guangxi Medical University, Nanning. bib.an@126.com

OBJECTIVE: To observe the clinical efficacy of Shenqi Fuzheng Injection (SFI) combined with chemotherapy in treating patients with advanced breast cancer.

METHODS: Sixty patients were randomly assigned to two groups by digital table, the control group and the treatment group, 30 in each group. All patients were treated with the same CTF regimen of chemotherapy for 21 days as one therapeutic cycle, while those in the treatment group were given SFI additionally in the meanwhite. The therapeutic efficacy was evaluated after 2 cycles of treatment by observing the changes of short-term efficacy, TCM syndrome, quality of life and immune function, as well as the adverse reaction.

RESULTS: The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05). The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05). The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.

CONCLUSION: For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.

PMID: 18386580 [PubMed - in process]

1: Zhong Yao Cai. 2007 Mar;30(3):377-80. Links

[Effect of Fuzheng Peiben therapy on dendritic cell in patients with breast cancer]

[Article in Chinese]

Li HS, Fang CH, Wang YD, Su XC, Yang B, Qi YC, Liu CL, Lu MY.

Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.

OBJECTIVE: To investigate the repairing mechanism of Fuzheng Peiben Therapy on cellular immunofunction in patients with breast cancer on cellar and molecular level. METHODS: The tumor tissue and axillary lymph node samples were evaluated with the flow cytometry for CD83, CD80, CD86 before and after neoadujvant therapy.

RESULTS: The levels of CD83, CD80, CD86 were singificantly decreased in group A (treated with surgery only), B (treated with neoadujvant chemotherapy plus surgery) and C (treated with neoadujvant chemotherapy plus surgery with shenqi Fuzheng Injection) compared with that in normal team (P < 0.05 or 0.01); The levels of CD83, CD80, CD86 were significantly decreased in group A, B and C compared between before and after neoadujvant chemotherapy (P < 0.05 or 0.01); They were not significantly decreased between group A and group C (P > 0.05).

CONCLUSION: The cellular immunity was inpaired considerably by neoadujvant chemotherapy. Neoadjuvant chemotherapy combined with Shenqi Fuzheng Injection can enhance the cellular immunity considerably.

PMID: 17634051 [PubMed - in process]

borstkanker, chinese kruiden